繰越利益剰余金、投資有価証券売却損、研究開発費
- 【期間】
| 年度 | 繰越利益剰余金 | 投資有価証券売却損 | 研究開発費 |
|---|
| 2017/03 | 52.7億 | | - | | 19.3億 | |
| 2017/09 | - | | - | | 9.07億 | -53% |
| 2018/03 | 56.5億 | +7.3% | - | | 18.9億 | +108% |
| 2018/09 | - | | - | | 10.6億 | -44% |
| 2019/03 | 55.5億 | -1.9% | - | | 21.9億 | +107.6% |
| 2019/09 | - | | 3百万 | | 10.8億 | -50.7% |
| 2019/12 | - | | 3百万 | ±0% | - | |
| 2020/03 | 57.4億 | +3.5% | 3百万 | ±0% | 22.9億 | +112.1% |
| 2020/09 | - | | - | | 10.3億 | -55% |
| 2021/03 | 70.6億 | +23% | 0 | -100% | 21.8億 | +111.3% |
| 2021/09 | - | | - | | 10.8億 | -50.3% |
| 2022/03 | 108億 | +53.1% | - | | 21.3億 | +96.5% |
| 2022/09 | - | | - | | 11.8億 | -44.6% |
| 2023/03 | 125億 | +15.4% | 10百万 | | 24.6億 | +108.2% |
| 2023/09 | - | | - | | 12.3億 | -50.1% |
| 2024/03 | 122億 | -1.8% | - | | 25.1億 | +104.6% |
